BSE Live
Sep 30, 16:01Prev. Close
1061.50
Open Price
1072.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 30, 15:47Prev. Close
1061.40
Open Price
1076.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
Cash Flow of Jubilant Pharmova (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
Net Profit/Loss Before Extraordinary Items And Tax | 980.60 | 170.50 | 27.78 | 630.45 | 1,212.01 | |
Net CashFlow From Operating Activities | 1,072.10 | 971.30 | 660.67 | 837.54 | 1,784.27 | |
Net Cash Used In Investing Activities | 487.70 | -607.90 | -544.41 | -380.37 | -739.01 | |
Net Cash Used From Financing Activities | -1,452.70 | -432.50 | -156.68 | -32.60 | -1,709.39 | |
Foreign Exchange Gains / Losses | 24.80 | 11.60 | 70.53 | 57.29 | 12.26 | |
Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | -76.98 | |
Net Inc/Dec In Cash And Cash Equivalents | 131.90 | -57.50 | 30.10 | 481.86 | -728.86 | |
Cash And Cash Equivalents Begin of Year | 956.40 | 1,013.90 | 983.82 | 501.96 | 1,230.81 | |
Cash And Cash Equivalents End Of Year | 1,088.30 | 956.40 | 1,013.92 | 983.82 | 501.96 |
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
20.07.2025
16.06.2025
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
16.05.2025
Jubilant Pharmo Consolidated March 2025 Net Sales at Rs 1,928.80 crore, up 9.68% Y-o-Y
16.05.2025
Jubilant Pharmo Standalone March 2025 Net Sales at Rs 217.30 crore, up 5.59% Y-o-Y
18.01.2021
Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher
12.07.2019
Jubilant Life Sciences Q1 PAT may dip 10.4% YoY to Rs. 181.4 cr: Prabhudas Lilladher
12.04.2019
Jubilant Life Sciences Q4 PAT seen up 36.3% YoY to Rs. 211.2 cr: Prabhudas Lilladher
11.01.2019
Jubilant Life Science Q3 PAT seen up 13.8% YoY to Rs. 241.8 cr: ICICI Direct